Systemic sclerosis (SSc), an autoimmune disease, may cause significant osteopenia due to activation of the IL4Rα/ mTOR pathway. Mesenchymal stem cell transplantation (MSCT) can ameliorate immune disorders in SSc via inducing immune tolerance. However, it is unknown whether MSCT rescues osteopenia phenotype in SSc. Here we show that MSCT can effectively ameliorate osteopenia in SSc mice by rescuing impaired lineage differentiation of the recipient bone marrow MSCs. Mechanistically, we show that donor MSCs transfer miR-151-5p to the recipient bone marrow MSCs in SSc mice to inhibit IL4Rα expression, thus downregulating mTOR pathway activation to enhance osteogenic differentiation and reduce adipogenic differentiation. Moreover, systemic delivery of miR-151-5p is capable of rescuing osteopenia, impaired bone marrow MSCs, tight skin, and immune disorders in SSc mice, suggesting that miR-151-5p may be a specific target for SSc treatment. Our finding identifies a previously unrecognized role of MSCT in transferring miRNAs to recipient stem cells to ameliorate osteopenia via rescuing a non-coding RNA pathway.
Introduction
Systemic sclerosis/scleroderma (SSc) is a connective tissue disorder characterized by progressive fibrosis of the skin, internal organ dysfunction, vasculopathy, and autoimmune rheumatic conditions [1] . Osteopenia of the vertebrae and other bones are commonly observed in SSc patients [2] [3] [4] [5] [6] . It has been suggested that bone loss in SSc patients may be due to immobilization, and medical treatments such as use of corticosteroids [7] . However, the detailed pathophysiological mechanism of bone defects in SSc patients is largely unknown.
Fibrillin-1 (Fbn1)-mutant tight-skin mice (B6.Cg-Fbn1Tsk/J; Tsk/ + ), an established SSc model, show significantly reduced femoral bone mineral density (BMD) and abnormal trabecular bone microarchitecture [8] . Recent studies indicate that type 2 helper T-cell (T H 2) infiltration and interleukin-4 (IL4), a key T H 2 cytokine, play a critical role in the regulation of fibrotic tissue deposition and bone marrow mesenchymal stem cells (BMMSCs) [9] . Downregulation of the IL4/IL4Rα signaling pathway in Tsk/ + mice can rescue fibrotic and osteoporotic phenotypes, suggesting that IL4 signaling contributes to the pathological process in SSc [10, 11] .
Systemic MSC transplantation (MSCT) has been used to treat a variety of human diseases such as graft versus host disease (GvHD), systemic lupus erythematosus (SLE), diabetes, rheumatoid arthritis, myocardial infarction, liver fibrosis, inflammatory bowel disease, autoimmune encephalomyelitis, periodontitis, sepsis and scleroderma [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . At the molecular level, MSCT may employ a paracrine cytokine secretion mechanism to regulate recipient immune response, thereby achieving therapeutic effects [24] [25] [26] [27] . In addition, MSCT is able to induce immune tolerance and ameliorate autoimmune phenotypes in SSc through activation of the Fas/Fas ligand pathway, leading to apoptosis of activated T cells [28, 29] . However, it is unknown whether MSCT ameliorates the osteoporotic phenotype and rescues impaired BMMSCs in SSc.
MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional regulators of gene expression [30] . It has been shown that coding and non-coding RNAs can be transferred between cells by small vesicles called exosomes [31] [32] [33] . Releasing large amounts of exosomes is one mean by which MSCs communicate with surrounding cells, implying that exosome-mediated cellular content transfer may serve as a novel mechanism offering therapeutic effects in MSCT [34, 35] . In this study, we show that MSCT transfers miR-151-5p to Tsk/ + recipients, rescuing impaired lineage differentiation of BMMSCs and osteopenia via regulating the IL4Rα/mTOR pathway.
Results

MSCT rescues osteopenia in Tsk/ + mice by regulating osteo-/ adipo-genic lineage differentiation of recipient BMMSCs
Tsk/ + SSc mice exhibit significantly reduced bone volume and increase of bone marrow adipocytes [8, 11] . Since MSCT is able to ameliorate the osteoporotic phenotypes observed in SLE and ovariectomized (OVX) mice [13, 36, 37] , we hypothesized that this therapeutic effect could extend to SSc. We therefore used allogeneic MSCT to treat Tsk/ + mice at 8 weeks of age and examined the therapeutic effects at 16 weeks of age ( Figure  1A ). MicroCT and histological analysis confirmed that BMD and distal femoral trabecular bone volume of Tsk/ + mice were markedly decreased compared with the control wild-type (WT) littermates ( Figure 1B-1D ). BMMSC transplantation (MSCT) significantly rescued BMD and trabecular bone volume in Tsk/ + mice ( Figure 1B-1D) . A histomorphometric analysis indicated that osteoblast and osteoclast numbers in the femurs of Tsk/ + mice using alkaline phosphatase (ALP) immunohistochemical and tartrate-resistant acid phosphatase (TRAP) staining, respectively, were significantly reduced when compared to the control littermates ( Figure 1E and 1F). MSCT significantly restored osteoblast and osteoclast numbers in the femurs of Tsk/ + mice ( Figure 1E and 1F). In addition, serum levels of soluble receptor activator of nuclear factor κB ligand (sRANKL) and type I collagen cross-linked telopeptide (CTX) were significantly reduced in Tsk/ + mice ( Figure 1G and 1H). MSCT markedly improved the serum levels of CTX and sRANKL ( Figure 1G and 1H), suggesting that bone volume loss is mainly caused by insufficient osteoblast function in Tsk/ + mice. To further confirm this observation, we performed a calcein-labeling assay to show that bone turnover rate was decreased in Tsk/ + mice, whereas MSCT significantly improved bone formation rate ( Figure 1I ).
To examine whether MSCT rescued BMMSC lineage differentiation in Tsk/ + mice, we isolated BMMSCs from MSCT-treated and untreated Tsk/ + mice. Our analysis revealed that the number of colony forming unit-fibroblasts (CFU-F) was significantly reduced in Tsk/ + mice compared to the control group, while MSCT significantly elevated the numbers of CFU-F ( Figure 2A ). When cultured under osteogenic induction conditions, Tsk/ + BMMSCs showed impaired osteogenic differentiation, as indicated by reduced mineralized nodule formation (assessed by alizarin red staining) and reduced expression of the osteogenic genes runt-related transcription factor 2 (Runx2), ALP, and osteocalcin (OCN) ( Figure  2B and 2C). MSCT was able to rescue impaired osteogenic differentiation of BMMSCs from Tsk/ + mice, as observed by increased mineralized nodule formation and expression of Runx2, ALP, and OCN ( Figure 2B and 2C). We next showed that BMMSCs derived from Tsk/ + mice generated less new bone than BMMSCs from the control group at 8 weeks post implantation using an established in vivo BMMSC implantation assay, in which 4 × 10 6 BMMSCs with hydroxyapatite tricalcium phosphate (HA/TCP) particles as a carrier were subcutaneously implanted into immunocompromised mice ( Figure 2D ). The impaired Tsk/ + BMMSCs were rescued by MSCT as indicated by increased in vivo bone formation ( Figure  2D ). In addition to impaired osteogenesis, Tsk/ + mice showed a markedly increased number of adipocytes in the bone marrow ( Figure 2E ). MSCT largely diminished numbers of adipocytes in the bone marrow of Tsk/ + mice ( Figure 2E Figure 2F and 2G). Based on these results, we conclude that the osteopenia in Tsk/ + mice is associated with altered lineage differentiation of BMMSCs, resulting in a decreased rate of bone formation. MSCT successfully ameliorates osteopenia in SSc mice via res- , and MSCT-treated Tsk/ + mice. Scale bar, 25 µm. All experimental data were verified in at least three independent experiments. Error bars represent the s.d. from the mean values. ***P < 0.005; **P < 0.001; *P < 0.05. + BMMSCs under the adipoinductive conditions. All experimental data were verified in at least three independent experiments. Error bars represent the s.d. from the mean values. ***P < 0.005; **P < 0.001; *P < 0.05.
cuing BMMSC lineage differentiation.
MSCT transfers miR-151-5p to Tsk/ + -recipient BMMSCs to rescue impaired osteo-/adipo-lineage differentiation
Since T H 2 cell infiltration and activation of IL4 signaling may contribute to SSc disease phenotypes [9- ( Figure 3A and 3B) . This finding prompted us to further examine how MSCT regulates IL4Rα expression in Tsk/ + BMMSCs. As MSCs are able to transfer miRNAs to surrounding cells in cancer and other disease models [38] [39] [40] , here we asked whether miRNAs, which are small non-coding RNAs (~22 nucleotides) capable of silencing gene expression at post-transcriptional level [41] , are involved in MSCT-mediated regulation of IL4Rα expression. We used a software available online, MicroCosm Targets, to computationally identify 19 miRNAs that may target Il4rα gene expression (Supplementary information, Table S1 ). Although the levels of several miRNAs were increased after MSCT treatment in SSc mice, qPCR analysis showed that only miR151-5p was significantly decreased in Tsk/ + BMMSCs ( Figure 3C ). After MSCT treatment, the level of miR-151-5p was significantly increased in Tsk/ + BMMSCs, suggesting that IL4Rα expression may be regulated by miR-151-5p ( Figure 3C ). To further confirm the functional role of miR-151-5p, we used different amounts of miR151-5p mimic and inhibitor to treat BMMSCs and found that 25 pmol miR151-5p mimic and inhibitor provided optimal effects on regulating IL4Rα expression in BMMSCs (Supplementary information, Figure S1 ). We treated Tsk/ + BMMSCs with a miR-151-5p mimic to increase the levels of miR-151-5p and found that Il4rα expression was significantly decreased ( Figure 3D Figure 3H and 3I) . In contrast, miR-151-5p inhibitor treatment reduced the levels of miR-151-5p, elevated the expression levels of Il4rα in WT BMMSCs ( Figure 3J and 3K), and impaired osteogenic differentiation, as indicated by reduced mineralized nodule formation ( Figure  3L ), downregulation of Runx2, ALP, and OCN ( Figure  3M ), an elevated number of Oil red O-positive cells (Figure 3N) , and upregulation of the adipogenic genes PPARγ and LPL ( Figure 3O ).
As miR-151-5p is 100% identical in mice and humans (Supplementary information, Figure S2A ), we reasoned that human miR-151-5p may also target human Il4rα, as predicted by microRNA.org (Supplementary information, Figure S2B ). We further confirmed that miR-151-5p inhibitor treatment significantly reduced the levels of miR-151-5p (Supplementary information, Figure S3A Figure S4A and S4B). Next, we used miR-151-5p mimic to treat IL4-induced human BMMSCs and found increased levels of miR-151-5p and reduced expression levels of Il4rα (Supplementary information, Figure S4C and S4D). In addition, we showed that osteogenic differentiation of IL4-induced human BMMSCs was significantly improved after miR-151-5p mimic treatment, as indicated by alizarin red staining to show increased mineralized nodule formation and western blotting to show elevated expression of Runx2, ALP, and OCN (Supplementary information, Figure S4E and S4F). Conversely, the elevated adipogenic differentiation in IL4-induced human BMMSCs was significantly reduced in the miR151-5p mimic treatment group, as indicated by a decreased number of Oil red O-positive cells and downregulation of PPARγ and LPL (Supplementary information, Figure S4G and S4H). Collectively, these data suggest that MSCT transferred miR-151-5p to Tsk/ + -recipient BMMSCs to block the IL4Rα pathway and rescue impaired lineage differentiation of recipient cells.
MSCT employs extracellular vesicles to rescue Tsk/
+ BMMSCs To determine how MSCT transfers miR-151-5p to recipient cells, we co-cultured WT BMMSCs with Tsk/ + BMMSCs in a transwell system to examine whether miR-151-5p can be transferred in vitro. After 3 days of co-culture, we observed elevated intracellular levels of miR-151-5p, decreased Il4rα gene expression, and improved osteogenic differentiation in Tsk/ + BMMSCs, as assessed by qPCR, alizarin red staining, and western blotting experiments, respectively ( Figure 4A-4C ). These data suggest that WT BMMSCs may release miR-151-5p to regulate Tsk/ + BMMSCs. As EVs, which include exosomes [42] , have been shown to carry RNAs for intercellular crosstalk [31] [32] [33] , we next examined whether To examine the role of Rab27a in exosome-mediated miR-151-5p transfer, Rab27a siRNA was co-transfected with miR151-5p-Cy3 into WT BMMSCs to show that miR-151-5p-Cy3 accumulated in the transfected BMMSCs compared to the scrambled siRNA transfected group, indicating that exosome-mediated miR-151-5p transfer was blocked by Rab27a. Scale bar, 25 µm. (G-K) After exosomes derived from WT BMMSCs were used to treat Tsk/ + BMMSCs, qPCR analysis showed elevated intracellular levels of miR-151-5p (G) and reduced expression levels of Il4rα (H), along with elevated mineralized nodule formation, as assessed by alizarin red staining (I), and increased expression of the osteogenic genes Runx2, ALP, and OCN, assessed by western blotting (J). When implanted into immunocompromised mice subcutaneously, increased new bone formation was observed (K). All experimental data were verified in at least three independent experiments. Error bars represent the s.d. from the mean values. ***P < 0.005; **P < 0.001; *P < 0.05. the secretion of EVs by BMMSCs can rescue impaired Tsk/ + BMMSCs. Using an siRNA approach to knockdown rab27a expression (Supplementary information, Figure S5A ) to block extracellular vesicle (EV)/exosome secretion [43] , we found that rab27a knockdown attenuated WT BMMSC-mediated rescue of intracellular miR-151-5p levels and Il4rα expression, as well as osteogenic differentiation in Tsk/ + BMMSCs ( Figure 4A-4C ). Next, we confirmed that purified EVs/exosomes from BMMSCs expressed exosome-specific markers CD63 and CD81 by western blotting (Supplementary information, Figure S5B ) and then we labeled miR-151-5p with Cy3 red fluorescent dye to show its co-localization with the exosome marker CD63 in BMMSCs (Supplementary information, Figure S5C ). In order to examine whether miR-151-5p can transfer between cultured BMMSCs, we co-cultured Tsk/ + BMMSCs with miR151-5p-cy3-transfected WT BMMSCs, conditioned medium from transfected BMMSCs, and EVs/exosomes from transfected BMMSCs. We showed that miR-151-5p can be transferred through EVs to Tsk/ + BMMSCs ( Figure 4D ) along with elevated levels of intracellular miR151-5p ( Figure 4E ). To further confirm EV/exosome-mediated miR-151-5p transfer, we used rab27a siRNA to block EV/exosome release in WT BMMSCs and found that miR151-5p transfer was markedly inhibited ( Figure 4F ). When EVs from WT BMMSCs were added to cultured Tsk/ + BMMSCs, the levels of intracellular miR-151-5p were increased, and the expression levels of Il4rα were decreased ( Figure 4G and 4H ). In addition, the EV treatment was able to improve osteogenic differentiation of Tsk/ + BMMSCs, as assessed by increased mineralized nodule formation, upregulation of the Runx2, ALP, and OCN, and increased in vivo bone formation ( Figure 4I -4K). To address whether MSCT releases EVs/exosomes in Tsk/ + mice, we transfected the CD63-GFP reporter vector into BMMSCs and performed MSCT in Tsk/ + mice. After MSCT, immunofluorescence (IF) staining showed that CD63 co-localized with the BMMSC marker CD105 in both the femur and skin in Tsk/ + mice (Supplementary information, Figure S5D ). We next labeled BMMSCs with red fluorescent dye, followed by transfection of the CD63-GFP reporter vector and performed MSCT in Tsk/ + mice to show that transplanted BMMSCs were not engrafted into the femur or skin in Tsk/ + mice (Supplementary information, Figure S5E ). To assess whether EVs/ exosomes transfer miR151-5p in vivo, we co-transfected the CD63-GFP reporter vector with Cy3-labeled miR151-5p into BMMSCs and performed MSCT in Tsk/ + mice. The data showed that MSCT-released CD63-GFP + EVs were co-localized with Cy3-miR151-5p, indicating that MSCT was associated with the secretion of exosomal miR151-5p in Tsk/ + mice (Supplementary information, Figure S5F ). Taken together, these experimental data indicate that MSCT-released EVs transferred miR151-5p to Tsk/ + BMMSCs to rescue the disease phenotypes. We next infused EVs into Tsk/ + mice to observe their in vivo therapeutic effects. After intravenous infusion into Tsk/ + mice, contents of EVs were detected in bone marrow cells at 24 h post transplantation (Supplementary information, Figure S5G ) and Tsk/ + BMMSCs showed elevated intracellular levels of miR-151-5p ( Figure 5A ) and reduced expression levels of Il4rα ( Figure 5B ). To further confirm that the increased miR151-5p was mainly transferred by EVs, we used miR151-5p inhibitor to generate miR-151-5p-depleted EVs and infused them into Tsk/ + mice, and found that miR-151-5p-depleted EVs failed to elevate intracellular levels of miR-151-5p ( Figure 5A ) and reduce expression levels of Il4rα ( Figure  5B ). Increased osteogenic differentiation was also observed upon infusion of EVs, as assessed by alizarin red staining to show elevated mineralized nodule formation ( Figure 5C ), western blotting to show upregulation of the osteogenic genes Runx2, ALP, and OCN ( Figure 5D ), and in vivo implantation to show elevated bone formation capacity ( Figure 5E ), while miR-151-5p-depleted EVs failed to increase osteogenic differentiation ( Figure  5C -5E). In contrast, BMMSCs from EV-treated, but not miR-151-5p-depleted EV-treated Tsk/ + mice, showed a significant reduction in adipogenic differentiation, as shown by decreased numbers of Oil red O-positive cells and downregulation of the adipogenic genes PPARγ and LPL (Figure 5F and 5G). MicroCT and histological analysis showed that EV-treated Tsk/ + mice have significantly increased BMD and trabecular bone volume compared to untreated Tsk/ + mice ( Figure 5H and 5I), whereas miR-151-5p-depleted EVs failed to increase BMD and trabecular bone volume ( Figure 5H and 5I) . The numbers of adipocytes in EV/exosome-treated, but not miR-151-5p-depleted EV-treated Tsk/ + mouse bone marrow were significantly reduced when compared to untreated Tsk/ + mice, as assessed by Oil red O staining ( Figure 5J ). These data indicate that EVs/exosomes play an important role in the regulation of miR-151-5p levels to rescue Tsk/ + BMMSC function and osteopenia. To further confirm MSCT releasing EVs/exosomes to rescue Tsk/ + phenotypes, we blocked EV/exosome secretion in vivo by treating BMMSCs with rab27a siRNA and performed MSCT in Tsk/ + mice. The therapeutic effects of sirab27a-treated BMMSCs were significantly decreased when compared to the control MSCT group, as assessed by microCT and histological analysis to show BMD and trabecular bone volume (Supplementary information, Figure S6A and S6B) and Oil red O staining to show adipocytes in Tsk/ + mouse bone marrow (Supplementary information, Figure S6C ).
Overexpression of miR-151-5p rescues disease phenotypes in Tsk/
+ mice In light of miR-151-5p negatively regulating IL4Rα expression in Tsk/ + BMMSCs, we next assessed the effects of overexpressing miR-151 in Tsk/ + mice by ad-enoviral vector with a green fluorescent protein (GFP) reporter (Ad-miR-151). Ad-miR151 (2 × 10 9 p.f.u.) or an empty vector (Ad-GFP) was injected into Tsk/ + mice three times a week for up to 4 weeks ( Figure 6A ). Forty-eight hours after the last injection, we used immunofluorescent analysis to show GFP expression in AdmiR-151-treated Tsk/ + bone marrow cells ( Figure 6B ). Ad-miR-151-treated Tsk/ + BMMSCs were collected to show elevation of the intracellular levels of miR-151-5p ( Figure 6C ) and reduced expression levels of Il4rα (Figure 6D) . Osteogenic differentiation of BMMSCs from Ad-miR-151-treated Tsk/ + mice was markedly improved when compared to the Ad-GFP-treated Tsk/ + BMMSCs, as analyzed by alizarin red staining to show elevated mineralized nodule formation ( Figure 6E ), western blotting to show increased expression of the osteogenic genes Runx2, ALP, and OCN ( Figure 6F ), and in vivo BMMSC implantation to show elevated new bone formation ( Figure 6G ). In contrast, BMMSCs isolated from Ad-miR-151-treated Tsk/ + mice showed significantly less adipogenic differentiation than BMMSCs from Ad-GFPtreated Tsk/ + mice, as shown by a decreased number of Oil red O-positive cells and downregulation of PPARγ and LPL (Figure 6H and 6I) . Histological and microCT analysis showed that Ad-miR-151 treatment elevated BMD and trabecular bone volume compared to Ad-GFPtreated Tsk/ + mice ( Figure 6J and 6K). The number of adipocytes in the bone marrow of Ad-miR-151-treated Tsk/ + mice was significantly reduced compared to Ad-GFPtreated Tsk/ + mice, as assessed by Oil red O staining (Figure 6L ). To examine whether overexpressing miR151-5p can increase therapeutic effects of EVs, we treated BMMSCs with Ad-miR151 to generate miR151-overexpressed (miR151-OE) EVs and subsequently infused these EVs into Tsk/ + mice. Treatment with EVs from 0.2 × 10 6 BMMSCs is considered a standard dosage to generate a therapeutic response. Therefore, we infused 10% of this standard dose of EVs (i.e., EVs from 0.02 × 10 6 BMMSCs) from miR151-5p-overexpressed BMMSCs or control WT BMMSCs into Tsk/ + mice to examine whether miR151-5p overexpression in BMMSCs could elevate the therapeutic effects of EVs. The results showed that this small dose of EVs from miR151-overexpressed BMMSCs, but not from WT BMMSCs, had similar therapeutic effects to those observed in EVs from the 0.2 × 10 6 BMMSCs group, as assessed by microCT and histological analysis (Supplementary information, Figure S7A and S7B) and Oil red O staining (Supplementary information, Figure S7C ).
Next, we examined whether systemic infusion of AdmiR-151 rescues autoimmune and connective tissue disorders in Tsk/ + mice, which represent major phenotypes of SSc. To evaluate skin fibrosis, we found that skin hypodermal thickness was reduced to a level equivalent to the control group after systemic administration of Ad-miR-151 ( Figure 7A ). Tsk/ + mice showed increased levels of antinuclear antibody (ANA), anti-double strand DNA (dsDNA) IgG and IgM antibodies, creatinine in serum, and urine proteins ( Figure 7B-7F) . When compared to the Ad-GFP treatment group, Ad-miR-151 treatment significantly reduced the levels of ANA, dsDNA IgG and IgM, serum creatinine, and urine protein in Tsk/ + mice ( Figure 7B-7F) . As mature miR-151-5p is able to directly target Il4rα, a key component of T H 2 cytokine signaling in the regulation of fibrotic tissue deposition and bone homeostasis in SSc [9] [10] [11] , we hypothesized that systemic Ad-miR-151 infusion downregulates T H 2 differentiation in Tsk/ + mice. To evaluate the efficiency of in vivo Ad-miR-151 treatment, serum levels of miR-151-5p were examined by qPCR and we found a markedly decreased level of miR-151-5p in Tsk/ + mice compared to control littermates (Supplementary information, Figure S8A) . Ad-miR-151 treatment significantly elevated serum levels of miR-151-5p (Supplementary information, Figure S8A ). Flow cytometric analysis showed that Tsk/ + mice have significantly increased levels of T H 2 cells (Supplementary information, Figure S8B Figure S8C ). Moreover, we found that Ad-miR-151 treatment significantly reduced CD4 + IL4
+ T H 2 cell infiltration, a major pathological phenotype in Tsk/ + mice [9] [10] [11] , as confirmed by IF staining (Supplementary information, Figure S9D ). To further examine the relationship between miR-151-5p and reduced T H 2 cell differentiation, we infected naive Tsk/ + CD4 T cells with Ad-miR-151 to assess the effects on T helper cell differentiation, activated under either non-polarized T H 0 or T H 2 conditions. Ad-miR-151 treatment promoted a marked increase in miR-151-5p in differentiated T cells under T H 0 or T H 2 conditions (Supplementary information, Figure S8D ). In the presence of increased miR-151-5p, we observed downregulation of the T H 2 genes, Il4 and Gata3, compared to T cells infected with control Ad-GFP (Supplementary information, Figure S8E ). ELISA further confirmed that Ad-miR-151 treatment reduced T H 2 cytokine IL4 production under T H 0 or T H 2 conditions (Supplementary information, Figure S8F ). Flow cytometric analysis showed that Ad-miR-151 significantly decreased T H 2 cells under T H 0 or T H 2 conditions compared with Ad-GFP treatment (Supplementary information, Figure S8G ). These data prompted us to examine whether osteoclast numbers rebound after MSCT as a direct result of the transplant itself (transfer of miR-151-5p). We isolated osteoclast precursors from bone marrow and induced them to differentiate into osteoclasts by treating them with M-CSF and RNAKL. The results showed that IL-4 treatment significantly inhibited osteoclastogenesis, which mimics the microenvironment in Tsk/ + mice. Over- expression of miR151-5p with Ad-miR151 treatment inhibited IL4Rα expression in osteoclast precursors, along with significantly increased osteoclastogenesis (Supplementary information, Figure S10 ). These data suggest that MSCT may directly transfer miR151-5p via EVs to increase osteoclast numbers in Tsk/ + mice. Collectively, these data reveal that MSCT ameliorates disease phenotypes in Tsk/ + mice through downregulating IL4Rα signaling in recipient BMMSCs to rescue impaired osteo-/ adipogenic lineage differentiation via exosome-mediated miR-151-5p transfer (Supplementary information, Figure  S11 ), suggesting that miR-151-5p treatment may be a target-specific therapy for SSc.
SSc patients show decreased serum levels of miR-151-5p and elevated expression of IL4Rα/mTOR cascade in BMMSCs
In order to confirm that miR-151-5p-mediated downregulation of IL4Rα/mTOR signaling is relevant to SSc in human patients, we conducted a pilot clinical investigation to assess whether diminished miR-151-5p levels and activated IL4Rα/mTOR signaling can be observed in SSc patients. Twenty patients diagnosed with SSc and 20 age-and gender-matched normal controls were enrolled in this study (Supplementary information, Table S2 ). qPCR analysis showed that serum levels of miR-151-5p were markedly decreased in SSc patients compared to normal controls ( Figure 8A ). Flow cytometric analysis showed that CD4 + IL4 + T H 2 cells were significantly increased in the peripheral blood of SSc patients compared to the control group ( Figure 8B ). ELISA further confirmed that serum IL4 levels were significantly elevated in SSc patients ( Figure 8C ). In addition, we found that SSc patients had significantly elevated levels of serum TGFβ and upregulation of Il4rα in BMMSCs by ELISA and qPCR analysis, respectively ( Figure 8D and 8E) . As mTOR complex 2 (TORC2) may act upstream of TORC1 in Tsk/ + BMMSCs [11] , we showed that BMMSCs from SSc patients had upregulated expression of p-Raptor, p-Rictor, and p-mTOR ( Figure 8F ).
Discussion
As the first MSCT was successfully performed in severe acute GvHD patients in 2004 [12] , MSCs from different sources have been widely utilized to treat various diseases [44] [45] [46] . Previous studies proposed multiple mechanisms may contribute to the success of MSCbased immune therapies such as secretion of cytokines/ chemokines, cell-cell interactions, and epigenetic regulation [24, 28, 36] . Recently, allogenic MSC-based cell therapy showed efficacy in a HOCl-induced SSc murine model, which is a closer match to the human disease [47, 48] . These studies, combined with several recent publications, suggest that the safety and efficacy of allogenic MSC-based therapy make it a promising approach in treating autoimmune and non-autoimmune diseases [49] [50] [51] . MSCT not only rescues osteoporosis in Tsk/ + mice, but also rescues the autoimmune phenotype and skin fibrosis in Tsk/ + mice [28] . In addition, we observed that osteoclast numbers rebound after MSCT. It is possible that MSCT involves multiple mechanisms to rescue disease phenotypes in Tsk/ + mice and other autoimmune disorders. Due to the nature of allogeneic transplant, there is little evidence to support the persistence of the graft in the recipient. Transferring miRNA and functional cellular components may be one of the therapeutic mechanisms mediated by MSCT. In this study, we showed that systemic administration of BMMSCs transfers miR-151-5p to Tsk/ + -recipient BMMSCs to rescue impaired osteo-/ adipogenic differentiation of recipient cells. Previous studies indicated that exosomes could serve as a vehicle to transfer miRNAs between cells [34, 52] to regulate gene expression and have the potential to offer therapies for stroke, liver fibrosis, and cardiovascular diseases [53] [54] [55] . We found that recipient Tsk/ + BMMSCs are able to take miR-151-5p/exosomes from donor MSCs and reuse miR-151-5p to downregulate IL4Rα expression, resulting in the improvement of recipient cell function. In addition, MSCs are capable of producing large amounts of exosomes [56] . Therefore, exosome/miRNA transfer may play a significant role in MSCT-mediated therapies. It appears that MSCT exerts therapeutic effects through multiple mechanisms of interaction with recipient microenvironments; however, the detailed mechanism by which the recipient microenvironment affects MSCT-mediated exosome transfer is unknown.
Differentially expressed miRNA profiles related to inflammation and fibrosis have been identified in SSc patients [57, 58] . Previous studies suggest that miRNAs mainly modulate fibrosis-related genes such as collagens, metallopeptidases, integrins, TGFβ, DNA methyltransferase 1, and toll-like receptors [59] , which could partially explain why SSc phenotypes display marked heterogeneity and imply complex interplay between different pathogenic processes. Among these complex pathophysiological factors, T helper cell homeostasis is generally biased toward T H 2 with the production of high levels of cytokines IL4 and IL13 in SSc [9] . Disruption of IL4 or IL4Rα can rescue the fibrosis and osteopenia phenotypes, suggesting that IL4/IL4Rα signaling may have an essential role in the disease pathogenesis [10, 11] . Accordingly, we decided to use T H 2-highly activated Tsk/ + mice as an SSc mouse model in this study, even though the Tsk/ + model does not perfectly mimic the clinical and immunological features of human SSc. In the present study, we identified a novel target, miR-151-5p, which plays a critical role in regulating BMMSC differentiation via suppressing IL4Rα. Through transfection of miR151-5p mimic or adenovirus-mediated miR-151-5p overexpression, Tsk/ + BMMSC function is largely improved, implying that miR-151-5p-based therapy may be a target-specific approach to treat SSc patients. Previous studies showed that multiple miRNAs are capable of regulating the osteogenic differentiation of BMMSCs and maintaining bone homeostasis [60, 61] . Here we found that miR-151-5p mediated a lineage switch between osteogenic and adipogenic differentiation and rescued the osteopenia phenotype in Tsk/ + mice. Interestingly, human miR-151-5p is able to target hIl4rα expression in human BMMSCs. Also, SSc patients showed significantly reduced serum levels of miR-151-5p, raising the possibility of translating our findings to the clinic. A major challenge in clinical practice is new biomarker discovery, which can be used for better disease diagnosis and classification. Notably, miR-151-5p may be able to serve as a biomarker for SSc diagnosis.
Gene therapy has been widely used to replace defective protein-coding genes in many genetic diseases. Given the crucial roles of miRNAs in regulating gene expression and disease development, miRNAs are considered as potential therapeutic targets for gene therapy. Recently, miRNA-based gene therapy has been established in some diseases that may be caused by the loss or reduced expression of a particular miRNA [62] . Due to the inefficient delivery or degradation of miRNAs, viral vectors encoding short hairpin RNAs, which are processed in the cell into mature miRNAs, are a promising alternative method of miRNA delivery [63] . In this study, we overexpressed miR-151 in vivo using an adenoviral vector, which produces mature miR-151-5p in recipient cells. Overexpression of miR-151-5p significantly reduced Il4rα expression and rescued osteopenia in Tsk/ + mice, which encouraged us to examine whether adenovirus-mediated miR-151-5p overexpression could affect other organs. Indeed, SSc morbidity and mortality are strongly related to fibrosis and vasculopathy. Osteopenia may not be one of the most challenging issues in SSc. Our data indicated that Ad-miR151 treatment successfully reduced T H 2 cell differentiation and decreased T-cell infiltration in the hyperdermal area, suggesting that miR-151-5p-based gene therapy can achieve therapeutic effects in multiple organs in Tsk/ + mice. To carry out both effective and safe miR151-5p-based gene therapy, its potential off-target effects need to be further explored in future study.
Dysfunction of BMMSCs in Tsk/ + mice caused by altered IL4/IL4Rα signaling results in an osteopenia phenotype, suggesting that osteo-immunological effect on stem cell homeostasis contributes to the SSc phenotype.
Upregulation of osteogenesis and downregulation of adipogenesis by miR-151-5p mimic treatment via inhibition of Il4rα expression may help to rebuild BMMSC function and bone marrow homeostasis. miR151-5p can serve as a promising biomarker for SSc diagnosis and a therapeutic target in SSc treatment. Given the extensive roles of MSCT in treating various autoimmune diseases, it is possible that other miRNAs can be transferred to target other specific signaling pathways.
Materials and Methods
Animals
Female C57BL/6J and B6.Cg-Fbn1
Tsk /J (Tsk/ + ) mice were purchased from Jackson Lab and maintained in a C57BL/6J background at least 10 backcrosses. Age-matched female littermates were used in all experiments. Female immunocompromised nude mice (Beige nu/nu XIDIII) were purchased from Harlan. All animal experiments were performed under institutionally approved protocols for the use of animal research (University of Pennsylvania protocol number 805478).
Isolation of mouse BMMSCs
A single suspension of bone marrow-derived all nuclear cells (ANCs, 15 × 10 6 ) from femurs was seeded in 100 mm culture dishes (Corning) and incubated at 37 o C with 5% CO 2 . After 48 h, nonadherent cells were removed, and adherent cells were cultured for additional 14 days in alpha minimum essential medium (α-MEM, Invitrogen) supplemented with 20% fetal bovine serum (FBS), 2 mM l-glutamine (Invitrogen), 55 µM 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen). These adherent single colonies were passaged at passage one with frequent medium changes to eliminate potential hematopoietic cell contamination [64, 65] . Since previous publications indicated that numerous passages of murine BMMSCs in atmospheric oxygen culture conditions can lead to spontaneous transformation both in vitro and in vivo [66] [67] [68] , we used passage one mouse BMMSCs in this study. For CFU-F assay, 1 × 10 6 single-suspension ANCs were seeded in T25 cell culture flasks (Corning). After 16 days, the cultures were washed with PBS and stained with 1% toluidine blue solution with 2% paraformaldehyde (PFA, Sigma-Aldrich). The cell clusters were counted under microscopy and those with more than 50 cells were considered as colonies.
Allogenic MSCT of SSc mice
BMMSCs, isolated from C57BL/6J mice at passage one, were suspended in 200 µl PBS and intravenously infused into Tsk/ + SSc mice (0.1 × 10 6 cells per 10 g body weight) at 8 weeks of age. In the control group, Tsk/ + mice received PBS. Background-matched WT mice were infused with PBS intravenously as positive controls.
MicroCT analysis
After being harvested and fixed in 4% PFA, femurs were analyzed using a high-resolution Scanco µCT50 scanner (Scanco Medical AG, Bruttisellen, Switzerland). The specimens were scanned using a voxel size of 20 µm at 70 kVp and 200 µA. Datasets were analyzed using Amira 5.3.1 software (Visage Imaging, Berlin, Germany) for reconstructing images and measuring BMD.
Histology
To assess trabecular bone and bone marrow areas, femurs were fixed in 4% PFA and then decalcified with 5 % EDTA (pH 7.4), followed by paraffin embedding. Paraffin sections 6 m in thickness were stained with hematoxylin and eosin (H&E) and analyzed using NIH ImageJ software. For immunohistochemistry staining, paraffin-embedded sections were incubated with the ALP or IL4 antibodies (Santa Cruz Biotechnology, Inc., 1:400) at 4 o C for overnight, and then stained with VECTASTAIN UNI-VERSAL elite ABC kit and ImmPACT VIP peroxidase Substrate Kit (VECTOR) according to the manufacturer's instruction. For osteoclast activity quantification, TRAP-positive cells were identified as mature osteoclasts on the bone surface. De-paraffinized sections were re-fixed with a mixture of 50% ethanol and 50% acetone for 10 min, and then incubated in the freshly made TRAP solution for staining with 1.6% naphthol AS-BI phosphate in N, N-dimethylformamide, 0.14% fast red-violet LB diazonium salt, 0.097% tartaric acid, and 0.04% MgCl 2 in 0.2 M sodium acetate buffer at pH 5.0 for 10 min at 37 o C under a shield. Samples were counterstained with toluidine blue. All reagents for TRAP staining were purchased from Sigma-Aldrich. For double calcein labeling histomorphometric analysis, the mice were intraperitoneally injected with calcein (Sigma, 15 mg/kg body weight) prepared in 2% sodium bicarbonate solution at 10 days and 3 days before killing. Bone dynamic histomorphometric analyses for MAR and BFR/BS were performed according to the standardized nomenclature for bone histomorphometry under fluorescence microscopy (Olympus IX71, Japan).
ELISA
Peripheral blood serum was collected and analyzed using mouse ELISA Ready-SET-GO kits (eBioscience) for sRANKL, IFNγ, IL4, IL17, and IL10 protein levels, according to the manufacturer's instructions. CTX levels were analyzed with a mouse C-telopeptide of type I collagen ELISA kit (Novateinbio), according to the manufacturer's instructions. Human IL4 and TGFβ protein levels were analyzed using ELISA Ready-SET-GO kits (eBioscience), according to the manufacturer's instructions. Mouse ANA, anti-dsDNA IgG, anti-dsDNA IgM, and creatinine (Alpha Diagnosis) were measured using commercially available kits according to manufacturer's instructions.
In vitro osteogenic differentiation
BMMSCs were cultured under osteogenic inductive conditions, including 2 mM β-glycerophosphate (Sigma-Aldrich), 100 µM L-ascorbic acid 2-phosphate (Wako), and 10 nM dexamethasone (Sigma-Aldrich) in the growth medium. After 3 weeks of induction, matrix mineralization was detected by 1% Alizarin Red S (Sigma-Aldrich) staining, and the stained positive areas were quantified using NIH ImageJ software and shown as a percentage of the total area.
Co-culture of WT BMMSCs with Tsk/ + BMMSCs
A transwell system for 12-well plates (Corning) was used for co-culture experiments. In vivo BMMSC implantation 4 .0 × 10 6 BMMSCs, isolated from C57BL/6J, Tsk/ + , MSCT, exosome-treated, and Ad-miR151-treated mice, were mixed with HA/TCP ceramic powders (40 mg, Zimmer Inc.) and implanted into 8-week-old nude mice subcutaneously. At 8 weeks post implantation, the transplants were harvested, fixed in 4% PFA, and decalcified with 5% EDTA, followed by paraffin embedding. The 6 µm paraffin sections were stained with H&E, and bone volume was quantified by NIH ImageJ software as a percentage of the total area.
Adipogenic differentiation
For adipogenesis, BMMSCs were cultured under adipogenic inductive conditions, in growth medium containing 500 nM isobutylmethylxanthine (Sigma-Aldrich), 60 µM indomethacin (Sigma-Aldrich), 500 nM hydrocortisone (Sigma-Aldrich), 10 µg/ml insulin (Sigma-Aldrich), and 100 nM l-ascorbic acid phosphate. At 7 days post induction, the adipocytes were stained with Oil red O (Sigma-Aldrich), and positive cells were quantified under microscopy and shown as a number out of the total cells.
In vivo Oil red O staining
To quantify the adipocytes surrounding the trabecular areas, femurs were fixed in 4% PFA and decalcified with 5 % EDTA (pH 7.4), followed by cryosectioning and staining with Oil Red-O solution. Positive areas were quantified under microscopy and shown as a percentage of the total area.
Flow cytometry
For intercellular staining, T cells were stained with 1 µg anti-CD4-PerCP and CD25-APC antibodies for 30 min on ice. After washing and centrifuging, cells were stained with 1 µg anti-IFNγ-APC, IL4-PE, IL17-PE, or Foxp3-PE antibodies using a Foxp3 staining buffer kit (eBioscience). All antibodies were purchased from BD Bioscience. After staining, all samples were analyzed using FACS Calibur with CellQuest software (BD Bioscience).
Real-time PCR
Total RNA was isolated from the cultured cells using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Total RNA from culture medium, serum, and bone marrow supernatant was isolated using the miRNeasy Serum/Plasma Kit (Qiagen). For real-time PCR of mRNA, the cDNA was synthesized using SuperScript III (Life Technologies). The real-time PCR was performed using SYBR green supermix (Bio-Rad, Hercules, CA, USA) and gene-specific primers. For real-time PCR of mature miRNA, cDNA was synthesized using the miScript II RT Kit (Qiagen). Real-time PCR was performed using the miScript SYBR Green PCR Kit (Qiagen). RUN6 was used as an endogenous control for BMMSCs. MiR-39 was used as spike-in control for culture medium, serum, and bone marrow (Qiagen). Real-time PCR was detected on a CFX96 Real-Time PCR System (Bio-Rad).
Extracellular vesicles treatment for Tsk/ + BMMSCs
EVs were isolated from C57BL/6J murine-derived BMMSCs by ultracentrifuge. MSCs were cultured in exosome-depleted medium (complete medium depleted of FBS-derived exosomes by overnight centrifugation at 100 000 × g) for 48 h. Small EVs from culture supernatants were isolated by differential centrifugation at 300 g for10 min, 2 000 × g for 10 min, 10 000 × g for 30 min, and 100 000 × g for 70 min [31] . As EVs are not homogeneous [42] , we used an EXOCEP exosome quantitation kit (System Biosciences Inc.) to quantitate the number of vesicles. Also, we used Exo-flow kits (System Biosciences Inc.) containing CD63 beads to show the purity of the EVs after high-speed centrifugation (Supplementary information, Figure S12 ). For osteogenesis assay, BMMSCs were pretreated with EVs (20 µg/ml) or PBS for 3 days and then cultured under osteoinductive conditions for 3 weeks, followed by Alizarin Red S staining.
Extracellular vesicle treatment in Tsk/ + mice
For in vivo EV tracking, PKH-26 (Sigma)-labeled EVs were intravenously infused into Tsk/ + mice. At 24 h post infusion, the femurs were fixed in 4% PFA and then decalcified with 5% EDTA, followed by optimal cutting temperature compound (OPT, Sakura Finetek, Torrance, CA, USA) embedding. Frozen sections were prepared, and slides were mounted with Vectashield mounting medium containing DAPI (Vector Laboratories, Burlingame, CA, USA). For in vivo treatments, EVs (100 µg) suspended in 200 µl PBS or PBS (mock) were infused into Tsk/ + mice intravenously. Four weeks after the treatment, mice were killed for further analysis.
Ad-miR-151 treatment in Tsk/
+ mice miR-151 over-expressed Adenoviral-GFP vector (Ad-miR151, Applied Biological Materials Inc.) were amplified in HEK-293 cells, followed by purification and quantification using the ViraBind Adenovirus Miniprep Kit and QuickTiter Adenovirus Quantitation kit (Cell Biolabs Inc.) according to manufacturers' instruc-tions. Ad-miR151 (2 × 10 9 p.f.u.) or empty vectors were injected into the Tsk/ + mice three times a week for up to 4 weeks. Samples will be harvested immediately after therapy for BMMSC isolation, histological assessments, and autoimmune index analysis. For in vivo exosome tracking, Ad-miR151 (2 × 10 9 p.f.u.) or an empty vector was injected into the Tsk/ + mice. At 24 h post infusion, the femurs were fixed in 4% PFA and then decalcified with 5% EDTA, followed by OPT embedding. Frozen sections were prepared, and slides were mounted with Vectashield mounting medium containing DAPI.
T-cell purification and differentiation
For in vitro polarization experiments, mouse CD4 + CD62L + T lymphocytes were isolated from mouse total spleen cells using a magnetic sorting CD4 + CD62L + T cell Isolation Kit II (Miltenyi Biotec, Auburn, CA, USA), according to the manufacturer's instructions. To activate T cells under T H 0 condition, T cells were activated with plate-bound anti-CD3 and anti-CD28 (2 µg/ml each; BD Bioscience) in medium for 3 days. To activate T cells to T H 2 condition, cells were activated for 72 h with plate-bound anti-CD3, anti-CD28, IL4 (20 ng/ml, R&D Systems), and anti-IFNγ neutralizing antibodies (10 µg/ml, Biolegend).
Systemic sclerosis patients
This study was conducted in compliance with current Good Clinical Practice standards and in accordance with the principles set forth under the Declaration of Helsinki, 1989. The protocol (NCT00962923) was approved by the IRB of the Drum Tower Hospital of Nanjing University, Medical School, China. Informed consent was obtained from each patient.
Statistics
Comparisons between the two groups were analyzed using independent unpaired two-tailed Student's t-tests, and comparisons between more than two groups were analyzed using one-way ANOVA with the Bonferroni adjustment. P-values < 0.05 were considered statistically significant.
